• Research
    Fibrolamellar Cancer Foundation
    Featured journal publication:
    The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
    Patient resources
    Fibrolamellar Cancer
    Foundation
    Today's highlighted AYA cancer group:
    Research partners
    Fibrolamellar Cancer Foundation
    Research effort underway at Johns Hopkins University and Dracen Pharmaceuticals:
    previous arrowprevious arrow
    next arrownext arrow

    FCF is committed to finding a cure and supporting those impacted by fibrolamellar. 100% of donated funds are used to drive research.

    Donate Tissue

    Advance research by donating tumor tissue at no cost to you or qualifying researchers

    Find a Doctor

    Find a doctor by specialty and location

    Connect

    Connect with the fibrolamellar community

    Latest News and Announcements


    FCF Partners